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Background: HIV-1 Clade C (Subtype C; HIV-1C) is responsible for greater than 50% of infections worldwide. Unlike
clade B HIV-1 (Subtype B; HIV-1B), which is known to cause HIV associated dementia (HAD) in approximately 15% to
30% of the infected individuals, HIV-1C has been linked with lower prevalence of HAD (0 to 6%) in India and
Ethiopia. However, recent studies report a higher prevalence of HAD in South Africa, Zambia and Botswana, where
HIV-1C infections predominate. Therefore, we examined whether Southern African HIV-1C is genetically distinct and
investigated its neurovirulence. HIV-1 Tat protein is a viral determinant of neurocognitive dysfunction. Therefore, we
focused our study on the variations seen in tat gene and its contribution to HIV associated neuropathogenesis.
Results: A phylogenetic analysis of tat sequences of Southern African (South Africa and Zambia) HIV isolates with
those from the geographically distant Southeast Asian (India and Bangladesh) isolates revealed that Southern
African tat sequences are distinct from Southeast Asian isolates. The proportion of HIV − 1C variants with an intact
dicysteine motif in Tat protein (C30C31) was significantly higher in the Southern African countries compared to
Southeast Asia and broadly paralleled the high incidence of HAD in these countries. Neuropathogenic potential of
a Southern African HIV-1C isolate (from Zambia; HIV-1C1084i), a HIV-1C isolate (HIV-1IndieC1) from Southeast Asia and a
HIV-1B isolate (HIV-1ADA) from the US were tested using in vitro assays to measure neurovirulence and a SCID
mouse HIV encephalitis model to measure cognitive deficits. In vitro assays revealed that the Southern African
isolate, HIV-1C1084i exhibited increased monocyte chemotaxis and greater neurotoxicity compared to Southeast
Asian HIV-1C. In neurocognitive tests, SCID mice injected with MDM infected with Southern African HIV-1C1084i
showed greater cognitive dysfunction similar to HIV-1B but much higher than those exposed to Southeast Asian
HIV − 1C.
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Conclusions: We report here, for the first time, that HIV-1C from Southern African countries is genetically distinct
from Southeast Asian HIV-1C and that it exhibits a high frequency of variants with dicysteine motif in a key
neurotoxic HIV protein, Tat. Our results indicate that Tat dicysteine motif determines neurovirulence. If confirmed in
population studies, it may be possible to predict neurocognitive outcomes of individuals infected with HIV-1C by
genotyping Tat.
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HIV-1 Tat C31S polymorphism, Neuroaids, HIV dementiaBackground
Human immunodeficiency virus type 1 (HIV-1) associated
neurocognitive disorders (HAND) comprise a spectrum of
conditions that range from asymptomatic neurocognitive
impairment (ANI) and mild neurocognitive disorder
(MND) to the most severe form, HIV-associated dementia
(HAD) [1]. Distinct clades of HIV-1 or their recombinants
dominate a given geographic region. HIV − 1C, the pre-
dominant clade prevalent in Africa and Southeast Asia, is
responsible for greater than 50% of all new infections
worldwide [2]. Studies have reported a lower prevalence
(0%-6%) of HAD in countries where HIV-1C is the domin-
ant clade (e.g., India, Ethiopia) [3,4]. This is in contrast to
studies in geographic regions (E.g., United States) that show
higher prevalence of HAD (15 - 30%) where HIV-1B is
prevalent [5,6].
HIV-1 Tat protein is one of the key viral determinants
of neurocognitive disorders [7] Infiltration of mono-
nuclear phagocytes in brain tissue is a hallmark of HAD.
Tat, in addition to its key role in LTR-transactivation
during viral replication, plays a pivotal role in monocyte
chemotaxis and neurotoxicity. Monocyte chemotaxis
driven by Tat is mediated by both direct and indirect
processes. Direct chemotaxis has been demonstrated
in vitro using recombinant Tat protein and this activity
of Tat has been mapped to the C30C31 dicysteine motif
in Tat [8,9]. Such a dicysteine motif is also a key feature
of β-chemokines such as CCL2, MIP1α and RANTES
[8]. Tat has also been shown to induce the secretion of
CCL2 from HIV-infected macrophages thus amplifying
the chemokine gradient which help recruit additional
mononuclear phagocytes across the blood–brain barrier
into the brain [10,11]. This property of Tat is based on
its homology to CCL2 and its ability to bind to CCR2
which triggers the induction of CCL2 by macrophages
exposed to Tat or HIV-infected cells [12]. The infiltra-
tion of HIV − infected macrophages in the brain leads to
the secretion of viral proteins such as Tat and gp120,
both of which have been shown to be neurotoxic [13,14].
In vivo, the presence of HIV proteins is known to result in
the loss of integrity of neuronal dendritic arbor in frontal
lobe and hippocampus and this is associated with neuronal
apoptosis [7,15-17].We previously showed that in ~90% of clade C HIV
isolates, tat gene displays a C31S polymorphism and is
defective for monocyte chemotaxis [18]. In vitro Boyden
chamber assays using HIV-infected monocyte-derived
macrophage (MDM) supernatants showed that monocyte
recruitment by the Indian clade C HIV-1CIndieC1-infected
medium was significantly lower than that by the US clade
B HIV-1BADA [19]. Depletion of Tat protein from the
HIV-infected MDM supernatants by immune-adsorbtion
abrogated the differential monocyte recruitment by the
two clades of HIV-1. Based on these findings, we had pro-
posed that the chemotaxis defect associated with Tat C31S
polymorphism is responsible for the lower prevalence of
HAD in India [18]. We used a severe combined immuno-
deficiency (SCID) HIV Encephalitis (HIVE) mouse model
in which intracranial injection of clade B HIV-infected
MDMs leads to neuropathology and neurocognitive defects
that parallel those found in HAD patients [20,21]. In this
model, clade C HIVIndieC1 isolate caused milder neuropath-
ology and reduced neurocognitive deficits compared with
clade B isolate (HIV-1BADA) [19]. To understand the
mechanism underlying clade differences between B and C
Tat proteins, Campbell et al. examined Tat-binding to
CCR2, intracellular calcium release in response to CCR2-
Tat interaction, monocyte migration and the induction of
TNF-α [22]. They showed that while clade B Tat specific-
ally binds CCR2, induces robust levels of intracellular
calcium influx and TNF-α and causes monocyte migration,
clade C Tat (with a C31S substitution) was defective for
these functions. In addition to the induction of CCL2, it is
known that HIV-1 Tat induces several proinflammatory
cytokines. Several groups have shown that in vitro purified
recombinant HIV-1B Tat induces monocytes to produce
proinflammatory cytokines to a greater extent than does
HIV-1C Tat [22-25].
The mechanism of neurotoxicity of HIV-1 Tat protein
is N-methyl-d-aspartic acid (NMDA) receptor-dependent.
Two main mechanisms of NMDA receptor activation by
HIV-Tat have been described. In one, an interaction of
HIV-Tat with surface receptors, such as low-density lipo-
protein receptor-related protein (LRP) and formation of a
macromolecular complex leads to neuronal apoptosis [26].
Second, a direct binding of HIV-Tat protein to the (LRP)
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Furthermore, it has been shown that NMDA receptor acti-
vation is clade dependent in that TatB protein bound to
NMDA receptor, while TatC did not [28].
In sharp contrast to reports from India that showed
low prevalence of HAD, recent studies from three countries
in Southern Africa where HIV-1C is the predominant
clade have reported a much higher prevalence of HAD
or HAND. South Africa and Botswana have reported a
25% and 38% incidence of HAD respectively [29-32],
while Zambia has reported a 22% incidence of HAND
[32]. Southern Africa and Southeast Asia are the two
main geographic regions where HIV-1C is prevalent. We
hypothesized that the Southern African HIV-1C isolates
are genetically distinct from those circulating in
Southeast Asia with respect to their neuropathogenic
potential. Based on previous findings that have implicated
tat polymorphism as being responsible for clade differences
in the incidence of HAD, we characterized HIV-1 Tat
exon 1 from both geographical regions. We analyzed
not only the sequences available in the databases from
countries where HIV-1C is prevalent, but also the
sequences derived from newly recruited patients in selected
countries. We report here that tat sequences from
Southern African HIV-1 isolates are genetically distinct
from those in Southeast Asian countries. We also
found that a greater proportion of Southern African
HIV − 1C isolates examined (11% to 26%) encoded
dicysteine motif C30C31, whereas much lower proportions
(1-3%) of HIV-1C from Southeast Asia encoded this motif.
To determine if the higher incidence of neuropathogenesis
observed in Southern Africa is due to this higher frequency
of variants with dicysteine motif in Tat, we carried out func-
tional analysis. Using both in vitro and mouse models, we
compared the neuropathogenic properties of: (i) a Southern
African HIV-1C isolate from Zambia with a dicysteine motif
in Tat, HIV-1C1084i [33]; (ii) a Southeast Asian isolate from
India, HIV-1CIndieC1 with a C31S substitution in Tat (iii) a
HIV-1B isolate with a dicysteine motif in Tat known to
cause neuronal damage and neurocognitive deficits in
SCID-HIVE mouse model, HIV-1BADA. We report that
in vitro, the Southern African HIV-1C isolate, in sharp
contrast to Southeast Asian HIV-1CIndieC1, behaved similar
to HIV-1B isolates in its robust ability to recruit monocytes,
induce β chemokines and cause apoptosis of human neu-
rons. We also found that the increased monocyte recruit-
ment and greater neurotoxicity of the Southern African
HIV-1C isolate HIV-1C1084i (with a dicysteine motif in Tat)
is due to Tat protein using immuno-depletion. Importantly,
in the SCID HIVE mouse model, HIV-1C1084i caused greater
neurocognitive dysfunction compared to the Southeast
Asian HIV-1CIndieC1. Our study further corroborates
the critical role that the Tat dicysteine motif plays in
neuropathogenesis and suggests that it may be possibleto use Tat genotyping to predict the neurocognitive
outcomes of patients infected with HIV-1C.
Results
Geographical variation in HIV-1C Tat Exon I
Based on the higher HAD prevalence rates in several
Southern African countries compared to that in India,
we hypothesized that the Southern African HIV-1C iso-
lates are genetically distinct from those circulating in
Southeast Asia. To test this hypothesis, we compared
the full-length HIV-1C sequences derived from selected
Southeast Asian (India, China and Myanmar) and Southern
African (South Africa, Zambia and Botswana) countries
(Ethiopian samples could not be obtained. Thus, we have
limited our studies to Southern African countries). The
Southern African samples were obtained from clinics
in Cape Town, South Africa and Lusaka, Zambia. The
Southeast Asian samples were from Bangalore, India
and Dhaka, Bangladesh. Phylogenetic analysis of full-length
HIV-1C sequences revealed distinct genetic differences
between HIV-1C isolates from Southern African countries
and those from Southeast Asia (Figure 1A). Next, we
performed population sequencing of tat exon 1 from HIV-
1 derived from clinical blood samples from two distinct
geographical regions (Southern Africa & Southeast Asia)
where HIV-1C is the predominant clade. Our analysis
indicated that the HIV-1C Tat sequences from South
Africa and Zambia formed a separate cluster segregat-
ing from the Southeast Asian HIV-1C sequences from
India and Bangladesh (Figure 1B). Interestingly, the
most distinguishing feature of Tat sequences from
South Africa and Zambia was the relatively common
occurrence of variants with an intact C30C31 motif
(26% and 20% respectively), which are rare among
sequences from India and Bangladesh (3% and 2%
respectively; Figure 2A). Previously, when Tat sequences
from worldwide were analyzed as a single group, the S31
residue emerged as a signature residue for HIV-1C Tat
(frequency: 0.89) [18], while for non-clade C HIV-1 Tat,
C31 was a signature residue (frequency: 0.99) [18]. In
order to verify that the increased frequency of CC motif is
unique to HIV-1 derived from Southern Africa, we also
analyzed Los Alamos database for HIV-1 Tat sequences
from South Africa, Zambia, Botswana and India. These
results paralleled those obtained from analyzing the clinical
isolates in that the Southern African isolates exhibit a
greater frequency of occurrence of C30S31 dicystine motif
(Figure 2B). This striking disparity in the proportion of
variants with dicysteine motif between Southern Africa and
Southeast Asia broadly reflects the HAD prevalence data
from these regions [3,29,31,32,34]. Therefore, we predicted
that Southern African isolates with a C30C31 motif in HIV-
1 Tat are more neurovirulent. We have carried out a series
of in vitro and in vivo experiments to test our prediction.
Figure 1 Phylogenetic analysis using full-length clade C sequences from diverse geographical locations. A. The graphic represents
maximum likelihood phylogenetic tree using full − length clade C sequences from Southeast Asia (India, China and Myanmar) and Southern-Africa
(South Africa, Zambia and Botswana) with reference clade B as out-group. The analysis identified a genetic divergence of HIV-1CIndieC1
(C.IN.93IN901 marked with filled Blue Circle) and HIV-1C1084i (C.ZM.HIV1084i marked with Red square) with distinct phylogenetic clusters.
B. Clinical isolates from two different geographical locations (Southern-Africa and Southeast Asia; n = 250) were included in the Maximum
Likelihood (ML) phylogenetic tree along with the reference HIV-1C sequences from the Los Alamos database from Zambia, Botswana, South
Africa and India (n =21) and HIV-1B sequences (n = 4) from the US, Netherlands, Thailand and France (outliers). Only the representative sequences
were chosen from Los Alamos Database to avoid “cohort effect” in the phylogenetic analysis. The tree was constructed in MEGA 5 [35] software,
with general time reversible with inverse gamma distribution (GTR + G + I), which has been predicted as the best-fit model. The Southern African
sequences are indicated by filled squares (Red: Zambia and Pink: South Africa) and Southeast Asian sequences were marked with filled circles
(Green: Bangladesh and Blue: India). C. The Predicted amino acid sequence of tat gene from the Zambian HIV-1C molecular clone HIV-11084i is
aligned with sequences from representative virus isolates of HIV-1B (HIV − 1BJR−CSF; HIV-1BADA) and HIV-1C (HIV-1CMJ4; HIV-1CIndieC1) as well as
consensus sequences using ClustalW software. Clade C signature amino acid residues previously defined by Ranga et al. [18], present in the
majority of HIV-1C Tat sequences in the Los Alamos database [36], are Clade C signature amino acid residues previously defined by Ranga et al.
[18], present in the majority of HIV-1C Tat sequences in the Los Alamos database [36], are indicated via asterisks below consenus clade C
sequence (CON_C). With the exception of C31, all these residues are conserved across all clade C isolates. Dots represent the residues identical
with the consensus of the respective clade. Residues in red indicate C30C31/C30S31 motif in Tat. Sequences are grouped by clade and indicated
on left.
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In order to test our prediction, a replication competent
Southern African HIV-1C isolate retaining a dicysteine
motif would be necessary. For this purpose, we exploiteda Zambian HIV-11084i that was previously isolated from
a pediatric patient. Previous analysis of this molecular
clone showed that it was an intra-clade recombinant,
where gag sequences clustered with Asian HIV-1C, while
Figure 2 Geographic variation in the frequency of HIV-1C Tat CC variants. A. Frequency of HIV-1 Tat sequences with CC and CS from
HIV-1-infected populations from Lusaka (Zambia), Cape Town (South Africa), Bangalore (India), and Dhaka (Bangladesh). B. Frequency of CC and
CS variants in the sequence database among HIV-1 Tat sequences in countries where HIV-1C predominates. Sequences were downloaded from
the Los Alamos database and aligned using Clustal-W software. Frequency of sequences with CC and CS at positions 30, 31 were calculated and
plotted as stacked graphs. The numbers below the bars (n) are the total independent sequences analyzed in each case.
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[33]. Comparison with other full-length sequences from
the database confirmed that it was representative of
Southern African isolates (Figure 1A). In the same analysis,
we included full-length HIV-1C sequences from Southeast
Asia and confirmed that the Southern African isolate
(HIV-1C1084i) was phylogenetically different from Southeast
Asian isolates (Figure 1A). Further, the ClustalW alignment
of the predicted amino acid sequence of HIV-1C1084i tat
exon I [33] with the consensus HIV-1B and HIV-1C
sequences and other HIV-1B and C isolates (Figure 1C)
revealed that this Tat sequence retains homology to
other HIV-1C Tat proteins over its entire length and it
was not a recombinant. However, HIV-1C1084i Tat does
not display the C31S polymorphism that is commonly
present in HIV-1C Tat sequences. This analysis along
with the fact that HIV-1C1084i gag, pol, and env sequences
mapped to HIV-1C in phylogenetic analysis makes it
an ideal virus to examine the neurotoxic potential of a
Southern African isolate [33].
Southern African HIV-1C1084i triggers increased monocyte
chemotaxis compared to Southeast Asian HIV-1C isolate
As monocyte infiltration is a hallmark of HAD, we first
compared the monocyte chemotaxis properties of Southern
African HIV-1C1084i-infected MDM supernatants with
those of Southeast Asian HIV-1C and a HIV-1B isolate. In
all of our studies, we have used HIV − 1C1084i to represent
the Southern African Tat dicysteine containing isolates, the
HIV-1CIndieC1 as the Indian isolate with the Tat C31S vari-
ant and the US − derived, HIV-1BADA as the clade B virusprototype with Tat dicysteine. For monocyte migration and
CCL2 induction, two additional virus isolates HIV-1BJR-CSF
(Clade B: Tat CC) [37] and HIV-1CMJ4 (Clade C: Tat CS)
[38] were also used.
The five HIV isolates indicated above were employed
to infect MDMs at variable inputs to match their rates
of replication, propagated for a period of 5 days and the
supernatants were evaluated to ensure that similar levels
of p24 (60 ng/ml − 80 ng/ml) were produced. We employed
a Boyden chamber with 3μ membrane barrier and
measured the ability of HIV-infected supernatants to
recruit monocytes across the membrane. We found that su-
pernatants from MDM − infected with HIV-1C1084i attracts
2-fold more monocytes compared to HIV − 1C viruses
lacking the dicysteine motif (HIV-1CIndieC1 and HIV-1CMJ4)
(t(6) = 9.86, p < 0.0001, n = 6), but less than that observed in
response to HIV-1B isolates (Figures 3A and 3B). HIV-1B
isolates (HIV-1BJRCSF and HIV-1BADA) attracted almost
3-fold more monocytes than HIV-1C isolates lacking
dicysteine motif (t(6) = 12.61, p < 0.0001, n = 6). Previously
it has been established that Tat and CCL2 present in the
MDM medium are responsible for increased chemotaxis
caused by HIV-1B. To determine whether Tat and/or
CCL2 are also responsible for increased chemotaxis
induced by HIV-11084i, HIV-1 Tat and CCL2 were
immuno-depleted from the medium using neutralizing
antibodies and monocyte migration assays were performed
[39]. Immuno-depletion of Tat resulted in the reduction in
recruitment of monocytes both by HIV-1BADA and HIV-
1C1084i-infected supernatants (Figure 3B). Immuno-deple-
tion of CCL2 also decreased the number of monocytes
Figure 3 (See legend on next page.)
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Figure 3 Differential monocyte recruitment by medium from macrophages infected with different HIV-1 isolates. A. Monocyte migration
caused by medium from HIV-1 infected MDMs. At least two isolate are used for each clade. HIV-1B isolates are shown in blue, HIV-1C isolates in
orange and HIV-1C1084i in green. Southern African HIV-1C1084i with a dicysteine motif in Tat induces significantly higher number of monocytes to
migrate compared to HIV-1C IndieC1 and HIV − 1CMJ4. Tat genotypes of each isolate are indicated in all three panels. B. Determining the soluble
factors in the infected MDM supernatant responsible for monocyte migration. Immuno-depletion of Tat and CCL2 resulted in significant (*)
reduction of monocyte recruitment both by HIV-1ADA (Clade B with dicysteine motif in Tat) and HIV-11084i (Clade C with dicysteine motif in Tat)
infected supernatants. Serial immuno-depletion of both CCL2 and Tat did not further reduce background migration. C. Fold increases, over
uninfected macrophages, in the level of CCL2 secreted by macrophages infected with various HIV-1 isolates: HIV-1BADA, HIV-1C1084i and
HIV-1CIndieC1. The levels of these chemokines in the media from uninfected control MDM cells were CCL2: 20.8ng/ml. HIV-1C1084i induced
significantly higher levels of CCL2 induction compared to HIV-1CIndieC1 and Controls. * p < 0.05.
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(Figure 3B). We note that despite immuno-depletion of Tat
or CCL2, there was a background level of monocyte migra-
tion. We have used low serum (2.5%) medium for 24 h to
reduce migration caused by chemotaxis factors present in
the human serum. However, this basal level of migration,
possibly caused by the presence of other β-chemokines in
the serum, could not be reduced further even after serially
immune-depleting both Tat and CCL2 (Figure 3B). Our
results suggest that the increased migration of monocytes
induced by HIV-1C1084i is largely due to presence of Tat
and CCL2 in the HIV-infected MDM medium.
We previously showed that HIV-1CIndieC1 induces
lower levels of CCL2 chemokine than HIV-1B in
infected MDMs correlating to their differences in
neuropathogenesis [19,40]. We analyzed CCL2 induction
for the different HIV-1 isolates studied above. Interestingly,
Southern African HIV-1C1084i induced 2.5 − fold greater
levels of CCL2 (t(16) = 10.13, p < 0.0001) compared to
uninfected controls (Control CCL2: 20.8 ng/ml) as well as
when compared to HIV-1CIndieC1, which caused no change
in the induction of CCL2 (t(16) = .3010, p > 0.5) levels from
uninfected controls (Figure 3C). These results suggest that
Southern African HIV-1C virus isolates with an intact
dicysteine motif, similar to HIV-1B isolates, are potent
inducers of chemokines, a key factor in recruitment of
mononuclear phagocytes to HIV-infected sites of the brain
in HAND (Figure 3C).
Southern African HIV-1C1084i Tat protein is more
neurotoxic when compared to TatC from HIV-1CIndieC1
We next examined the neurotoxicity of HIV-1C1084i
Tat when compared to HIV-1IndieC1 TatC and TatB
in vitro. Primary human neurons were treated with
conditioned medium obtained from HIV-infected MDM
and neuronal viability was quantified by using TUNEL
assay. Immunofluorescence was used to specifically de-
tect neurons (via staining for neurotubulin), apoptotic
cells (TUNEL staining) and nuclei (DAPI staining). The
neuronal viability was reduced by 60% when HIV-1C1084i–
infected MDM supernatants were used and greater than
80% when HIV-1BADA–infected MDM supernatants
were used (Figure 4A and 4B). Media from uninfectedMacrophages and HIV-1CIndieC1-infected MDMs resulted
in 12% to 25% cell death respectively (Figure 4A, 4B). In
order to determine the relative contribution of Tat to
neurotoxicity, the MDM supernatants were first de-
pleted of virions and free gp120 using broadly neutral-
izing envelope antibodies, and subsequently Tat was
immunodepleted from the medium. Neurons were exposed
to virus/gp120-immunoadsorbed medium with and
without immunodepletion of Tat. Neuronal apoptosis
was significantly reduced upon immunodepletion of
Tat from HIV-infected MDM medium (Figure 5A).
Key pathologic hallmarks of HIV associated dementia
are neuronal atrophy and the loss of dendritic arbor
[41]. In an in vitro setting, dendritic density, length and
thickness are a proxy indicator for signs of neuronal
atrophy. We chose to examine changes in dendritic
thickness in response to exposure of neurons to HIV-1
conditioned medium, to evaluate neurotoxicity. We
immune-depleted Tat from virus/gp120-adsorbed media
and tested the effect of both virus/gp120 − adsorbed and
virus/gp120- and Tat- adsorbed media on dendritic width.
Analysis of the width of the neuronal processes indicated
that human neurons treated with HIV-1C1084i- and
HIV-1BADA-infected MDM supernatants depleted for
both virus/gp120 and Tat proteins are significantly
(HIV-1C1084i: p value = 0.00007; HIV-1BADA: p value =
0.0071) thicker than infected MDM supernatants depleted
virus/gp120 (Figure 5B, 5C). We find that the dendrite
width increased to match the width of untreated neurons,
implicating Tat as one of the factors responsible for
neuronal atrophy observed.
Southern African HIV-1C1084i induces neurocognitive
deficits in SCID mice
The SCID HIVE is a well-characterized mouse model
suitable for testing HIV-induced neurovirulence and be-
havioral changes [20,21,42,43]. We intracranially injected
male SCID mice (4 groups of mice, 6 mice/group) with
human uninfected MDMs as well as MDMs infected
with one of the three viruses (HIV-1BADA, HIV-1CIndieC1
or HIV-1C1084i). The HIV-infected cultures were verified
to contain comparable levels of virus as measured by
p24 in the medium. Analysis of the mouse brain samples
Figure 4 Effect of HIV-infected MDM supernatants on neuronal apoptosis. A. HIV-1 infected MDM and uninfected MDM supernatant were
diluted with 100 μl of neurobasal medium and incubated with primary human neurons in Matek plates for 18 hours. HIV-1BADA and HIV-1C1084i
treatments lead to a greater loss of neuronal viability when compared to HIV-1CIndieC1 and uninfected supernatant. B. Tunnel stained primary
human neurons co-stained with anti-neurotubulin antibodies and DAPI (Prolong Gold antifader with DAPI, Invitrogen). The four panels show
representative fields for neurons treated with HIV-1BADA, HIV-1C1084i, HIV-1CIndieC1 and media from uninfected macrophages from left to right
respectively. The individual (or all) channels are indicated at left. * p < 0.05.
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number of p24 infected macrophages (4–8 p24-positive
cells per section) around the injection site. Cognitive assess-
ment using the Water Radial Arm Maze (WRAM) compar-
ing mice exposed to Southern African HIV − 1C1084i to
those exposed to Southeast Asian HIV-1CIndieC1 revealed
the Southern African isolate affects two orthogonal
measures of short term and long term working memory
(working memory correct: WMC and repeat reference
memory: RRM). When working memory load was
highest on trial 4 during the latter most portion of testing(days 11–12 post injection), there was a significant main
effect of exposure to HIV-1 isolates, HIV-1BADA and HIV-
1C1084i for WMC and RRM errors (WMC F(3,51) = 5.16,
p = 0.003; RRM F(3,51) = 7.58, p = 0.0001; Figures 6A, 6C,
& 6D). The HIV-1CIndieC1 exposed mice did not differ from
the Control group (post-hoc ps > 0.651; Figures 6A, 6C, &
6D), whereas the HIV − 1C1084i exposed mice and HIV-1B
ADA exposed mice committed more errors than the Control
group and HIV-1CIndieC1-exposed mice Figures 6A, 6C,
& 6D). Mice exposed to HIV-1C1084i, in spite of being
closely related to HIV-1CIndieC1, did not differ from mice
Figure 5 Neurotoxicity of Tat in HIV-1C1084i-infected MDM supernatant. A. HIV-infected media used in Figure 5 were used to pre-adsorb
HIV particles and/or free gp120 to eliminate confounding factors and the Tat protein from such media were further adsorbed using anti-Tat
antibodies to demonstrate the neurotoxicity specifically due to Tat from HIV − 1BADA and HIV-1C1084i but not HIV-1CIndieC1. For both panels A and
B, bars corresponding to medium depleted of virus/gp120 is shown by ↓, whereas those corresponding to medium depleted of both virus/gp120
and Tat protein are shown by ↓↓. B. Measurement of dendritic width shows HIV-1BADA & HIV-1C1084i cause significant decreases in dendritic
width. Use of virus-adsorbed medium and virus- plus Tat-adsorbed HIV-1BADA and HIV-1C1084i-infected medium as in Panel A above lead to
increase in dendrite width, but not in HIV-1CIndieC-infected medium, clearly demonstrating the role played by HIV-1C1084i Tat in neuronal atrophy.
C. Representative fields showing effect of Tat immune-depletion in HIV-1C1084i MDM media on dendrite width. The left top and bottom panels
show representative fields of primary neurons treated with HIV-1C1084i MDM media prior to Tat immuno-depletion and the right top and bottom
panels show increase in dendrite width following immune-depletion of Tat. * p < 0.05.
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6C, & 6D).
On test day 13 post-injection, a 45m delay was imposed
between trials 2 and 3 to increase the demand placed on
the working memory system of the mice. There was a
significant main effect for RRM on post-delay trials 3 & 4
(F(3,51) = 6.01, p = 0.0010; Figure 6B), with HIV-1C1084i or
HIV-1BADA (post-hoc ps < 0.0120), but not HIV-1CIndieC1,
exposed mice committing more RRM errors as compared
to the Control group (Figure 6B). For this measure, errors
increased in a linear fashion from control animals, who
committed no errors, to the HIV-1BADA exposed mice,
who committed the most errors (t(51) = 4.27, p < 0.0001;
Figure 6B). Our results demonstrate that exposure to
Southern African HIV-1C isolate with an intact dicysteinemotif in Tat causes working memory deficits similar to
that caused by clade B HIV-1.
To address the strength of the relationship between
each treatment group and the degree of working mem-
ory impairment, Cohen’s d was calculated between each
group from RRM errors during test days 11–12 trials 1–
4. The degree of working memory impairment, as com-
pared to the Control group, increased from the clade C
(HIV-1CIndieC1; d = 0.45) virus, to the clade C with an
intact dicysteine motif (HIV-1C1084i; d = 1.08) virus and
the clade B (HIV-1BADA; d = 1.53) virus demonstrating
the highest degree of working memory impairment
(Figures 6A, & 6C). The HIV-1CIndieC1 exposed mice
exhibited a lesser magnitude of working memory impair-
ment in comparison to the HIV-1C1084i (d = 0.76) and
Figure 6 Cognitive performance of SCID mice exposed to HIV-1 and controls evaluated on the WRAM during the asymptotic testing
phase (data represent mean ± SE). A. Analysis of working memory errors collapsed across days 11 and 12 and trials revealed Southern African
HIV-1C1084i and HIV-1BADA exposed mice made significantly more RRM errors than the Control (ps < 0.018) and HIV− 1CIndieC1-exposed mice B. RRM errors
committed on Day 13 post-45m delay trials 3 and 4, the Southern African HIV-1C1084i and HIV-1BADA but not HIV− 1CIndieC1 exposed mice committing more
RRM errors as compared to the Control group. Group rankings for RRM errors committed on the delay followed a linear trend, with the Control group
committing no errors, and the HIV-1BADA group committing the most. C. Analysis of Working Memory Correct errors committed on trial 4, when working
memory load was the highest HIV-1CIndieC1 exposed mice did not differ from the Control group, but the Southern African HIV-1C1084i and HIV-1BADA exposed
mice committed more errors. * p< 0.05; ^ p< 0.05 linear trend. D.Evaluation of Reference Memory Repeat errors committed on trial 4, the HIV-1C1084i and
HIV-1BADA (i.e., mice exposed to HIV-1 with an intact dicysteine motif) committed more working memory errors when compared to the Control and
HIV-1IndieC1 (clade C HIV-1 with C31S substitution in Tat) groups.
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tudes of working memory impairment between the
HIV-1C1084i and HIV-1BADA exposed mice were similar
(d = 0.13; Figures 6A, & 6C).
Discussion
We report that tat gene in the HIV-1 clade C isolates
circulating in Southern African countries (South Africa,
Zambia and Botswana) is evolutionarily distinct from
those in Southeast Asia (India and Bangladesh). Southern
African HIV-1C isolates displayed a uniquely higher pro-
portion of variants encoding Tat protein with a dicysteine
motif (C30C31) when compared to those in Southeast
Asian countries. The interesting correlation between the
proportion of viruses encoding Tat with a dicysteine motif
and the higher prevalence of HAD in these countries
[29-32] prompted us to examine the hypothesis that the
presence of a dicysteine motif in clade C Tat is a determin-
ant of neuropathogenesis. Evidence presented in this com-
munication includes neurocognitive data in SCID-HIVE
model as well as in vitro studies showing that a Southern
African variant HIV-1C isolate (HIV − 11084i) containing a
dicysteine motif in Tat displays a robust ability to both
recruit monocytes and to cause neurotoxicity.Previous studies examining HIV-1 env sequences from
Northeast India have concluded that Indian clade C has
evolved into a distinct sub-clade termed CIN [44]. More
recently, Neogi et al. [45] analyzed 168 HIV sequences
drawn from 4 distinct regions of India, systematically an-
alyzed gag, pol and env regions and concluded that the
Indian clade C HIV has evolved independently from
African clade C HIV over the last 40 years. They dated
the origin of the Indian clade C via the most recent
common ancestor (tMRCA) analysis and compared it to
tMRCAs determined for clade C HIV circulating in
other countries (Ethiopia, Zimbabwe and Brazil). This
analysis led them to conclude that the Indian clade C
probably originated from the African clade C, but has
evolved independently with little intermixing with African
clade C sequences [45,46]. It is generally thought that the
region-specific evolution of HIV-1 clades is likely due to
founder effects [44] although one cannot rule out the role
of host genetic factors in perpetuating specific variants in
that region [47].
The cysteine-rich domain is crucial for monocyte
chemotaxis function of HIV-1B Tat protein [8] as is the
case for β-chemokines [48]. The absence of dicysteine
motif in HIV-1C Tat is shown to be responsible for the
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1B and HIV-1C Tat proteins showed that B Tat induces
robust monocyte migration and causes the induction of
chemokines, such as CCL2, while HIV-1C Tat has only a
weak activity for both these properties [19]. Although it
is formally possible that clade differences may be due to
differential secretion or accumulation of Tat in the HIV-
infected MDM medium for these two clades of HIV, we
believe this to be unlikely. Li et al. [28] have previously
reported that cells transfected with HIV-1C and HIV-1B
Tat expression constructs secreted similar levels of Tat
proteins. Furthermore, using chemically synthesized
Tat proteins, Campbell et al. [22] showed that a HIV-1B
Tat protein binds to CCR2, induces intracellular calcium
flux, causes monocyte chemotaxis as well as induces
CCL2 and TNFα, while Tat from a Southeast Asian
HIV-1C (without a dicysteine motif ) did not. The same
group showed that Tat protein from a Southern African
HIV-1C isolate (Botswanan) retaining a dicysteine motif
was competent for monocyte chemotaxis and induced
CCL2 and TNFα at levels similar to HIV-1B Tat protein
[22]. In addition, a Southeast Asian patient isolate from
Bangalore encoding a Tat protein with an intact dicysteine
motif also displayed a phenotype similar to similar to
Southern African HIV-11084i (Additional file 1: Figure S1).
The use of HIV-1C1084i, a HIV-1C isolate from Zambia,
allowed us to confirm the hypothesis that the Southern
African dicysteine motif-containing HIV-1C isolates are
more neuropathogenic [33]. Despite the short time span of
SCID-HIVE model (4 weeks), the features exhibited in this
model (gliosis, neuronal atrophy and neurocognitive deficits)
are consistent with chronic encephalitis rather than an
acute inflammatory state [20,21,42,43]. This model
simulates the loss of memory and cognitive dysfunction
observed in patients suffering from HAD/HAND and pro-
vides an effective means to compare the effects of different
virus isolates [19]. The cognitive tests in mice suggest that
HIV-1C1084i isolate, by virtue of encoding a Tat protein
with an intact dicysteine motif, can be as neurotoxic as
HIV-1B viruses. Dicysteine motif of HIV-1 Tat has also
been shown to be critical for direct neurotoxicity [7,28].
Thus, in vitro data showing direct neurotoxicity of
HIV-1C1084i–infected MDM supernatants and SCID-HIVE
data showing neurocognitive defects caused by HIV1084i
together support the key role played by the dicysteine motif
in HIV neuropathogenesis.
Previous studies have shown that MDMs, either
infected with HIV-1B [19] or exposed to purified recom-
binant Tat protein from HIV-1B [19,23,25], lead to a
greater level of induction of inflammatory chemokines
such as CCL2 than HIV-1C or Tat protein derived from
it. β-chemokine levels are elevated in cerebrospinal fluid
of patients with HAD [49] and HIV-1 Tat is one of the
key viral proteins responsible for the induction of suchchemokines [10]. Our present study showed that when
an intact dicysteine motif is present in Tat (HIV-1C1084i),
a HIV-1C virus isolate is able to induce CCL2 in sharp
contrast to clade C isolates lacking the dicysteine motif
(HIV-1CIndieC1). Our results suggest that the intact
dicysteine motif is critical for the induction of inflammatory
chemokines that play a crucial role in development of
HAD/ HAND.
Earlier studies led to the idea that some clades of HIV-1,
such as clade C, cause reduced neuropathogenesis [3,4].
Our current results highlight the fact that all clade C HIV
isolates do not display a C30S31 polymorphism in the Tat
protein encoded by them. Furthermore, the presence of
variant clade C viruses with a C30C31 dicysteine motif
can be endowed with capacity to cause neuropathogenesis.
It is important to recognize that even though 99% of clade
B isolates display C30C31 motif, HAD is observed in
only a third of the HIV-1B-infected individuals. A
broad interpretation of our current finding is that all
clade C variants bearing Tat with C30C31 dicysteine
motif are neurovirulent. If this notion is true, although
unproven currently, it would suggest that unlike clade
B, clade C virus may contain other determinants outside of
tat gene, that when combined with the C30C31 motif,
increase neurovirulence. Additional studies would be neces-
sary to delineate the relative roles of Tat dicysteine motif
and other potential neurovirulent signatures elsewhere on
the Southern African subtype C isolates. One limitation of
our study is that our SCID-HIVE experiments were
conducted using single isolates for each of the three classes
examined. This limitation will be overcome as more of
well-characterized African isolates with an intact C30C31
become available. However, our conclusions are strongly
supported by multiple lines of evidence from various la-
boratories supporting the view that the C30C31 plays mul-
tiple key roles in neuropathogenesis (monocyte infiltration,
neurotoxicity and induction of proinflammatory cytokines)
[8,18,19,22-25,28,50]. Based on the findings reported here,
it may be possible to predict the neurocognitive outcomes
for individuals newly infected with HIV-1 clade C by deter-
mining the presence of C30C31 in tat gene. In order to
clinically validate our findings, it is necessary to conduct
systematic studies in countries where HIV-1C is the domin-
ant clade, by screening infected individuals for the presence
of C30C31 versus C30S31 followed by examining their
neurocognitive deficits to determine HAD.
Conclusions
Our results demonstrate that HIV-1C isolates from
Southern African countries are genetically distinct from
those circulating in Southeast Asia. A greater proportion of
viruses in Southern Africa display the neuropathogenesis-
associated dicysteine motif in HIV Tat protein resulting in
a large disparity in HIV associated neurocognitive disease
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with HIV-1 Tat displaying dicysteine motif show more
robust monocyte migration, neurotoxicity and cognitive
deficits in a SCID-HIVE model than Southeast Asian HIV-
1C isolates. We propose that it is possible to predict the
neurocognitive outcome in millions of HIV-1C infected
individuals by genotyping the HIV-1 Tat gene. Longitudinal
HIV-1 cohort studies in Southern Africa and Southeast
Asia with neuropsychiatric evaluations are required to
further substantiate our conclusions.
Methods
Primary neurons and HIV isolates
Primary neurons were isolated and cultured as described
earlier [51]. Centrifugally elutriated human monocytes
were purchased from University of Nebrasaka Medical
center. The monocytes were differentiated into macro-
phages by culturing in MCSF and 10% Human serum
for a period of 7 days.
HIV-1 isolates employed for our in vitro and mouse
model studies, HIV-1ADA (US clade B), HIV-1IndieC1
(Indian clade C isolate) and HIV-11084i (Zambian clade C)
were generated by transfection of molecular clone DNA
into 293T cells and the virus released was quantitated by
p24 Enzyme-linked immune-sorbent assay (ELISA; Applied
Biosystems, Inc). In experiments to measure monocyte
migration, two additional virus isolates HIV-1BJR-CSF
(Clade B: Tat CC) [37] and HIV-1CMJ4 (Clade C: Tat CS)
[38] were also used [19,39].
Sequence analyses, population studies and alignments
Study population
HIV-1-infected patient samples analyzed were from
Cape Town, South Africa; Lusaka, Zambia; Bangalore,
India and Dhaka, Bangladesh. In Bangalore and Dhaka,
new studies were initiated while pre-existing patient
samples in Cape Town and Lusaka were used to obtain
tat sequences for our analysis. Ethical approval for this
study was obtained from the Einstein Institutional Review
Board (IRB) as well as from all local IRBs. See Additional
file 2: Table S1 for patient demographics.
Full length sequence analysis
Full-length HIV-1C sequences derived from Southeast
Asian (India, China and Myanmar) and Southern African
(South Africa, Zambia and Botswana) countries where
HIV-1C is the predominant clade were obtained along with
Subtype B reference sequences from the Los Alamos HIV-1
database. The sequences were aligned using Clustal-W2.
Maximum likelihood phylogenetic tree was constructed
based on General Time reversible model with represen-
tative sequences. Phylogenetic analyses were conducted
in MEGA5 [35].Generating and analyzing of HIV-1 Tat sequences
For genotyping tat, whole blood was drawn from infected
patients. Genomic DNA was isolated from either peripheral
blood mononuclear cells or from whole blood and HIV-1
clade was determined based on gag and env sequencing
using Maximum Likelihood (ML) phylogenetic tree in Mo-
lecular Evolutionary Genetics Analysis version 5 (MEGA5)
[35]. HIV-1 tat exon 1 was PCR amplified from genomic
DNA using primer sequences shown in Additional file 3:
Table S2. Sequencing was via primers located well upstream
of Exon 1 (nucleotide 5781 from HxB2 reference clone).
The PCR primers were designed to amplify the entire tat
exon 1 from the 3′ end of the vpr (HXB2 position 5781) up
to the 5′ end of vpu (HXB2 terminal position 6242), with
the tat exon 1 lying between HXB2 position 5831 and
6045). Thus, the amplicon has a region of 50 nucleotides
upstream and 200 nucleotides downstream of the tat exon
1 sequence. All study sequences were screened for PCR
cross-contamination using neighbor joining phylogenetic
tree. All study sequences demonstrated well-separated
branches, indicating the absence of cross-contamination.
After excluding partial and problematic sequences, the
percent frequency of sequences with intact dicysteine mo-
tifs was determined. The data were plotted using Graphpad
Prism (v5.1, GraphPad Software, La Jolla, CA).
HIV-1 tat sequences that were already available prior
to our study were obtained from the Los Alamos database
from countries where HIV-1C was the most prevalent
clade. Tat amino acid sequences were generated by trans-
lation were aligned using Clustal-W2 [52]. Sequences with
premature stop codons in its open reading frame (ORF)
and frame-shifts were excluded. Total numbers of HIV-1C
Tat sequences with intact dicysteine motifs were enumer-
ated and percentages derived.
HIV-1 Infection of MDMs
Elutriated primary human monocytes (University of
Nebraska Medical Center) were differentiated into macro-
phages and infected with HIV-1BADA [53], HIV − 1CIndieC1
[54] or with HIV-1C1084i [33] and propagated for a period
of 14 days as described previously [19]. A comparable level
of virus production was achieved among different viruses
as described previously by varying the multiplicity of
infection to achieve similar levels of virions in the medium
following 14-day propagation. Equivalence of virus levels
between the cultures was determined by p24 staining of
infected MDMs [19,39] and by measuring the p24 levels
in the medium.
Monocyte migration studies and CCL2 induction
Monocyte migration
Human MDMs were cultured for 5 d under the same
conditions as described above. Approximately 2 × 105
MDMs were plated in the lower wells of a 24-well plate
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at an MOI of 0.1 for 1 h, HIV-1Indie-C1 (clade C with
C31S substitution in Tat) at an MOI of 0.01 for 3 h and
HIV-11084i (clade C with dicysteine in Tat) at an MOI of
0.1 for JRCSF, and a MOI of 1 for MJ4 for 5 d. ELISA
for p24 in the supernatants showed equal viral loads
(60 ng/ml to 80 ng/ml p24) for all viruses. Three hundred
microliters of HIV-1 infected MDM supernatant was
added to the bottom chamber and 500,000 monocytes
were added to the transwell. The number of monocytes
migrated were analyzed after 24 hours by counting the
cells in the bottom chamber using a hemocytometer. The
bottom well is treated with Accutase (Millipore) prior to
resuspending the cells from the bottom chamber to ensure
there are no adherent monocytes that are missed.
Tat and CCL2 immuno-depletion
Tat and CCL2 were immunodepleted from HIV-1
infected MDM supernatants using either anti-Tat (E 1.1;
[50]) or anti-CCL2 antibodies (MAb 279; R&D systems)
as described [19,39]. For this purpose anti-Tat and anti-
CCL2 antibodies were bound to Pansorbin beads
(Calbiochem, Cat no. 507861) on ice for an hour. After
incubation of the antibodies with the beads (Pansorbin)
the beads are centrifuged and resuspended in a small
volume, 25 μl, and added to the conditioned medium
obtained from the HIV-infected MDM. Following incu-
bation for an hour, the beads are pelleted and the super-
natant, without the beads, are used for the migration
assay as described above.
Measurement of CCL2
CCL2/MCP-1 levels were measured using an ELISA kit
from Invitrogen (MCP-1 Human ELISA Kit- KHC 1011)
in HIV-1-infected MDM supernatants collected on day
14 from five different virus isolates and from uninfected
MDMs. On Day 13, MDMs were incubated for 24 h in
fresh medium without human serum to eliminate the
contribution of CCL2 in human serum. The day 15 no-
serum supernatant was collected, and ELISA for CCL2
(R&D Systems) was performed in triplicates in three
separate experiments [19].
Neurotoxicity
Primary human neurons were isolated and cultured as
described earlier [51]. Approximately 100,000 primary
neurons were plated on coated MatTek well plates for a
period of 2 days and allowed to stabilize and differenti-
ate. HIV-1 infected MDM (HIV-1BADA(14.8 ng/ml),
HIV-1CIndieC (16.2 ng/ml), HIV-1C1084i (15.7 ng/ml))
& the uninfected MDM supernatant (100 μl) were
diluted with 100 μl of Neurobasal medium (Gibco) and
then added to primary Neurons. Following incubation
for 18 hours at 37°C, neurons were fixed and TUNEL assaywas performed using the TMR in situ hybridization kit
(Roche; Cat No. 12156792910). Neurons were also stained
using anti-neurotubulin antibodies (Abcam cat. No. 21058)
and 4′,6-diamidino-2-phenylindole (DAPI; Prolong gold
anti-fade agent with DAPI, Invitrogen, cat number, p36931)
to distinguish them from astrocytes. Image capture and
analysis was done using Nikon (NIS elements) advanced
research software. Percent apoptosis/survival was deter-
mined based on the proportion of cells with DAPI stain
that were TUNEL-positive. Dendrite width was measured
using Nikon (NIS elements) advanced research software
and median dendrite width was calculated using GraphPad
Prism (v5.1, GraphPad Software, La Jolla, CA).
SCID HIVE mouse model
Intracranial injection of HIV-infected MDMs
HIV-infected MDMs prepared as described above were
employed for intracranial injection. At the end of a 14-day
in vitro propagation of MDMs, prior to intracranial
injection, the p24 levels in the supernatants of MDMs
infected with HIV-1BADA, HIV-1C1084i and HIV-1CIndieC1
were 76.6 ng/ml, 63.8 ng/ml and 78.9 ng/ml respectively.
Approximately 105 MDMs, uninfected or infected with
one of the three viruses were injected intracranially (i.c.)
into 4-week old B6.CB17-Prkdc SCID/Szj male mice
(Jackson Laboratories) as before [19,55]. Upon analyzing
the mouse brain samples injected with the three different
isolates, they too exhibited a similar number of HIV-
infected macrophages (4–8 p24-positive cells per section)
around the injection site.
Cognitive assessment of mice
Twenty-four male mice (B6.CB17-Prkdc SCID/Szj) were
injected with MDMs (i.e., 6 HIV-1C1084i, 6 HIV-1BADA,
6 HIV-1CIndieC1 and 6 control, uninfected MDMs). Fol-
lowing the i.c. injection of MDMs, mice were allowed to
recover for 5 days followed by testing using win-shift
Water Radial Arm Maze (WRAM) as previously described
[19]. The win-shift WRAM utilizes water escape onto
hidden platforms as the reinforcer [19,55-57]. The testing
protocol included an asymptotic phase (days 11–12) used
for statistical analysis [56,58]. Working memory correct
(WMC) errors were defined as entries into an arm wherein
a platform had already been located, reference memory
(RM) errors were an initial entry into an arm that never
contained a platform, and reference memory repeat (RRM)
errors were repeat entries into an arm that never contained
a platform and were all quantified based on Jarrard and
colleagues’ [59] orthogonal measures. On day 13, a 45
minute delay was imposed between trials 2 and 3 to assess
retention of multiple items of spatial information [60]. The
dependent measures for performance on the delay day were
total WMC, RRM, and RM errors on trials 3 and 4, for
trials after the 45 minute delay.
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Statistical analysis for the in-vitro studies was performed
using Grouped Analysis and plotted in Graphpad Prism
5.1. For WRAM studies, data were analyzed using an
omnibus mixed model ANOVA with Treatment as the
between variable, and Days and/or Trials as the within
variable(s). Follow-up comparisons employed Fisher
protected least squares difference (PLSD) post-hoc tests
when a significant omnibus ANOVA was found. Using
SPSS (version 18, IBM, Somers, NY), polynomial contrasts
were employed to assess trends in the data between
treatment groups and errors committed on the WRAM.
Cohen’s d was calculated for specific pairwise comparisons
between the HIV-infected groups and the control group.
Cohen’s d was employed as a measure of effect size that as-
sesses the difference between two group means represented
in standard deviation units [61].
Endnote
Sequences generated for this manuscript have been
deposited in Genbank. The accession numbers are:
India- JQ241040-JQ241062 and JQ241064 - JQ241139;
Zambia- JX661510-JX661554; Bangladesh- JX675467-
JX675522; South Africa- JX675523- JX675569.
Additional files
Additional file 1: Figure S1. A new isolate of HIV-1CTatCC behaves
similar to HIV-11084i in stimulating monocyte migration and CCL2 release.
A. Monocyte migration caused by medium from HIV-1 infected PBMCs.
Southern African HIV-1C1084i and Indian HIV-1CIN1290SJ with a dicysteine
motif in Tat induce higher number of monocytes to migrate compared
to HIV-1C IndieC1 and Control. B. Fold increases, over uninfected PBMCs
(which produced 1ng/ml), in the levels of CCL2 secreted by PBMCs
infected with various HIV-1 isolates: HIV-1BADA, HIV-1C1290SJ, HIV-1C1084i
and HIV-1CIndieC1. HIV-1C1084i and HIV-1C1290SJ induced higher levels of
CCL2 release compared to HIV-1CIndieC1 and Controls. p values indicated
in panels A and B were calculated using Fisher’s PSLD test.
Additional file 2: Table S1. Patient demographics and clinical status.
Additional file 3: Table S2. Tat primers used in analysis of patient
samples.
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